- Home
- UWMC vs PHAR Comparison
UWMC vs PHAR Comparison
Compare UWMC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- PHAR
- Stock Information
- Founded
- UWMC 1986
- PHAR 1988
- Country
- UWMC United States
- PHAR Netherlands
- Employees
- UWMC N/A
- PHAR N/A
- Industry
- UWMC Finance: Consumer Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- PHAR Health Care
- Exchange
- UWMC Nasdaq
- PHAR Nasdaq
- Market Cap
- UWMC 872.1M
- PHAR 718.1M
- IPO Year
- UWMC N/A
- PHAR N/A
- Fundamental
- Price
- UWMC $4.31
- PHAR $10.60
- Analyst Decision
- UWMC Hold
- PHAR Strong Buy
- Analyst Count
- UWMC 8
- PHAR 3
- Target Price
- UWMC $6.86
- PHAR $30.00
- AVG Volume (30 Days)
- UWMC 5.6M
- PHAR 3.1K
- Earning Date
- UWMC 05-06-2025
- PHAR 05-08-2025
- Dividend Yield
- UWMC 9.30%
- PHAR N/A
- EPS Growth
- UWMC N/A
- PHAR N/A
- EPS
- UWMC N/A
- PHAR N/A
- Revenue
- UWMC $2,486,541,000.00
- PHAR $320,708,000.00
- Revenue This Year
- UWMC $7.37
- PHAR $13.31
- Revenue Next Year
- UWMC $22.42
- PHAR $7.68
- P/E Ratio
- UWMC N/A
- PHAR N/A
- Revenue Growth
- UWMC 10.39
- PHAR 24.13
- 52 Week Low
- UWMC $3.89
- PHAR $6.65
- 52 Week High
- UWMC $9.74
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- UWMC 47.87
- PHAR 62.25
- Support Level
- UWMC $3.89
- PHAR $10.02
- Resistance Level
- UWMC $4.25
- PHAR $10.89
- Average True Range (ATR)
- UWMC 0.18
- PHAR 0.27
- MACD
- UWMC 0.05
- PHAR 0.07
- Stochastic Oscillator
- UWMC 84.16
- PHAR 86.82
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.